01 46GILEAD SCIENCES INC
01 47176220
02 47635704
03 210039718
04 210039718*PED
05 47176220*PED
06 17390791
07 17390791*PED
08 47635704*PED
09 28148374
10 28148374*PED
11 28633219
12 28633219*PED
13 18754065
14 18754065*PED
15 48981103
16 48981103*PED
17 19296769
18 19296769*PED
19 29891239
20 29891239*PED
01 17Y
02 29Blank
01 23Y
02 23Blank
01 12025-01-07
02 12025-07-07
03 42026-08-27
04 82026-10-26
05 42027-02-27
06 82027-04-26
07 42029-09-03
08 42030-03-03
09 22030-04-30
10 22030-10-30
11 22032-08-15
12 22032-10-06
13 22033-02-15
14 22033-04-06
Patent Expiration Date : 2026-10-26
US Patent Number : 7635704
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203093
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2026-10-26
Patent Expiration Date : 2026-10-26
US Patent Number : 7635704
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203093
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2026-10-26
Patent Expiration Date : 2030-04-30
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 8633219
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2030-04-30
Patent Expiration Date : 2026-10-26
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 7635704
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2026-10-26
Patent Expiration Date : 2029-09-03
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 8148374
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-1279
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2032-08-15
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 8754065
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2032-08-15
Patent Expiration Date : 2032-08-15
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 9296769
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2032-08-15
Patent Expiration Date : 2029-09-03
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 9891239
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2030-04-30
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 8633219
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2030-04-30
Patent Expiration Date : 2029-09-03
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 8148374
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-1279
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
